Vertex lavishes $80M cash to expand gene therapy tool kit; Supernus bags a $300M CNS portfolio
→ Vertex’s bullish outlook wasn’t just manifested in its upbeat revision of the full-year guidance. Earlier this week, the Boston biotech handed over $80 million in cash to gene therapy upstart Affinia to engineer new AAV capsids to deliver a string of potential new treatments for Duchenne muscular dystrophy, myotonic dystrophy type 1 and cystic fibrosis. Affinia, which debuted to the biotech world just a month ago with AveXis veteran Rick Modi at the helm, is eligible for $1.6 billion in milestones.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
